229 related articles for article (PubMed ID: 16452213)
21. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma.
Lu KH; Wu W; Dave B; Slomovitz BM; Burke TW; Munsell MF; Broaddus RR; Walker CL
Clin Cancer Res; 2008 May; 14(9):2543-50. PubMed ID: 18451215
[TBL] [Abstract][Full Text] [Related]
22. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.
Wang MY; Lu KV; Zhu S; Dia EQ; Vivanco I; Shackleford GM; Cavenee WK; Mellinghoff IK; Cloughesy TF; Sawyers CL; Mischel PS
Cancer Res; 2006 Aug; 66(16):7864-9. PubMed ID: 16912159
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models.
Lee L; Sudentas P; Donohue B; Asrican K; Worku A; Walker V; Sun Y; Schmidt K; Albert MS; El-Hashemite N; Lader AS; Onda H; Zhang H; Kwiatkowski DJ; Dabora SL
Genes Chromosomes Cancer; 2005 Mar; 42(3):213-27. PubMed ID: 15578690
[TBL] [Abstract][Full Text] [Related]
24. Rapamycin: an anti-cancer immunosuppressant?
Law BK
Crit Rev Oncol Hematol; 2005 Oct; 56(1):47-60. PubMed ID: 16039868
[TBL] [Abstract][Full Text] [Related]
25. Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway.
Pore N; Jiang Z; Shu HK; Bernhard E; Kao GD; Maity A
Mol Cancer Res; 2006 Jul; 4(7):471-9. PubMed ID: 16849522
[TBL] [Abstract][Full Text] [Related]
26. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin.
El-Hashemite N; Walker V; Zhang H; Kwiatkowski DJ
Cancer Res; 2003 Sep; 63(17):5173-7. PubMed ID: 14500340
[TBL] [Abstract][Full Text] [Related]
27. An expanding role for mTOR in cancer.
Guertin DA; Sabatini DM
Trends Mol Med; 2005 Aug; 11(8):353-61. PubMed ID: 16002336
[TBL] [Abstract][Full Text] [Related]
28. Alternative phospholipase D/mTOR survival signal in human breast cancer cells.
Chen Y; Rodrik V; Foster DA
Oncogene; 2005 Jan; 24(4):672-9. PubMed ID: 15580312
[TBL] [Abstract][Full Text] [Related]
29. Differential IKK/NF-κB Activity Is Mediated by TSC2 through mTORC1 in PTEN-Null Prostate Cancer and Tuberous Sclerosis Complex Tumor Cells.
Gao Y; Gartenhaus RB; Lapidus RG; Hussain A; Zhang Y; Wang X; Dan HC
Mol Cancer Res; 2015 Dec; 13(12):1602-14. PubMed ID: 26374334
[TBL] [Abstract][Full Text] [Related]
30. TOR signaling.
Harris TE; Lawrence JC
Sci STKE; 2003 Dec; 2003(212):re15. PubMed ID: 14668532
[TBL] [Abstract][Full Text] [Related]
31. Unrestrained mammalian target of rapamycin complexes 1 and 2 increase expression of phosphatase and tensin homolog deleted on chromosome 10 to regulate phosphorylation of Akt kinase.
Das F; Ghosh-Choudhury N; Dey N; Mandal CC; Mahimainathan L; Kasinath BS; Abboud HE; Choudhury GG
J Biol Chem; 2012 Feb; 287(6):3808-22. PubMed ID: 22184110
[TBL] [Abstract][Full Text] [Related]
32. Mammalian target of rapamycin complex 1 activation sensitizes human glioma cells to hypoxia-induced cell death.
Thiepold AL; Lorenz NI; Foltyn M; Engel AL; Divé I; Urban H; Heller S; Bruns I; Hofmann U; Dröse S; Harter PN; Mittelbronn M; Steinbach JP; Ronellenfitsch MW
Brain; 2017 Oct; 140(10):2623-2638. PubMed ID: 28969371
[TBL] [Abstract][Full Text] [Related]
33. PTEN and rapamycin inhibiting the growth of K562 cells through regulating mTOR signaling pathway.
Cheng ZY; Guo XL; Yang XY; Niu ZY; Li SH; Wang SY; Chen H; Pan L
J Exp Clin Cancer Res; 2008 Dec; 27(1):87. PubMed ID: 19115995
[TBL] [Abstract][Full Text] [Related]
34. Analysis of mTOR signaling by the small G-proteins, Rheb and RhebL1.
Tee AR; Blenis J; Proud CG
FEBS Lett; 2005 Aug; 579(21):4763-8. PubMed ID: 16098514
[TBL] [Abstract][Full Text] [Related]
35. GADD34 inhibits mammalian target of rapamycin signaling via tuberous sclerosis complex and controls cell survival under bioenergetic stress.
Watanabe R; Tambe Y; Inoue H; Isono T; Haneda M; Isobe K; Kobayashi T; Hino O; Okabe H; Chano T
Int J Mol Med; 2007 Mar; 19(3):475-83. PubMed ID: 17273797
[TBL] [Abstract][Full Text] [Related]
36. The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo.
Kawaguchi T; Yamashita Y; Kanamori M; Endersby R; Bankiewicz KS; Baker SJ; Bergers G; Pieper RO
Cancer Res; 2006 Dec; 66(23):11331-40. PubMed ID: 17145879
[TBL] [Abstract][Full Text] [Related]
37. Hypoxia-induced energy stress regulates mRNA translation and cell growth.
Liu L; Cash TP; Jones RG; Keith B; Thompson CB; Simon MC
Mol Cell; 2006 Feb; 21(4):521-31. PubMed ID: 16483933
[TBL] [Abstract][Full Text] [Related]
38. Deregulation of cap-dependent mRNA translation increases tumour radiosensitivity through reduction of the hypoxic fraction.
Rouschop KM; Dubois L; Schaaf MB; van den Beucken T; Lieuwes N; Keulers TG; Savelkouls KG; Bussink J; van der Kogel AJ; Koritzinsky M; Wouters BG
Radiother Oncol; 2011 Jun; 99(3):385-91. PubMed ID: 21665307
[TBL] [Abstract][Full Text] [Related]
39. Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA-21 up-regulation in hepatocytes.
Vinciguerra M; Sgroi A; Veyrat-Durebex C; Rubbia-Brandt L; Buhler LH; Foti M
Hepatology; 2009 Apr; 49(4):1176-84. PubMed ID: 19072831
[TBL] [Abstract][Full Text] [Related]
40. Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.
Verheijen JC; Richard DJ; Curran K; Kaplan J; Lefever M; Nowak P; Malwitz DJ; Brooijmans N; Toral-Barza L; Zhang WG; Lucas J; Hollander I; Ayral-Kaloustian S; Mansour TS; Yu K; Zask A
J Med Chem; 2009 Dec; 52(24):8010-24. PubMed ID: 19894727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
